Cellular programming and reprogramming: from somatic cell nuclear transfer to induced pluripotency

Reading time: 7 minutes

For most of the twentieth century, cell specialisation was considered a one-way street. Once a cell committed to becoming skin, or blood, or nerve, the assumption was that it could not go back. Its fate was fixed. The discovery that this assumption is wrong, that differentiated cells retain the genetic information needed to become any cell type and can be persuaded to act on it, is one of the most consequential findings in modern biology.

This article traces how that understanding developed, from the first nuclear transfer experiments in frogs through the cloning of mammals to the creation of induced pluripotent stem cells. It explains the methods, what they revealed about cellular identity, and why they matter for anyone working in or around stem cell technology today.

The question of nuclear equivalence

The story begins with a question that preoccupied embryologists for decades: do cells lose genetic information as they specialise, or do they retain the full complement of genes and simply use different subsets?

In the late nineteenth century, August Weismann proposed that development involved the progressive loss of genetic material, with different cell lineages retaining only the genes they needed. This hypothesis was testable, but only with techniques that did not yet exist [1].

The experimental tool that made the test possible was nuclear transfer, also called nuclear transplantation. The principle is straightforward: replace the genetic information contained in an egg with that contained in the nucleus from a more specialised cell, and observe whether the resulting construct can develop normally. If it can, the specialised nucleus must still contain the genetic instructions to build an entire organism.

Frogs: Gurdon and the proof of nuclear totipotency

Robert Briggs and Thomas King performed the first successful nuclear transfers in the frog Rana pipiens in 1952, showing that nuclei from early embryonic cells could support normal development when transplanted into enucleated eggs. However, they reported that nuclei from later-stage, more differentiated cells could not [2].

It was John Gurdon, working at the University of Oxford with Xenopus laevis, who overturned this conclusion. In 1962, Gurdon published results showing that nuclei taken from the intestinal epithelium of feeding tadpoles, cells that were functionally specialised, could generate normal swimming tadpoles when transferred into enucleated eggs [3]. Some of these tadpoles were later raised to fertile adulthood [4].

This was a landmark. It established that specialised cells retain the full genetic programme needed to build an organism. The DNA is not lost or irreversibly silenced during differentiation. Rather, it is regulated. The cell's identity is determined by which genes are active, not by which genes are present, and that pattern of activity can, under the right conditions, be reversed.

Gurdon's approach relied on a technical innovation: the use of ultraviolet irradiation to destroy the egg's own genetic information while leaving the cytoplasmic components, the proteins and other molecules that enact reprogramming, intact. He also used a genetic marker, a mutation affecting the number of nucleoli in Xenopus cells (structures within nuclei), to confirm that the resulting tadpoles carried the transplanted genome rather than surviving genetic information from the host egg cell [3].

Mammals: Dolly and somatic cell nuclear transfer

The extension of nuclear transfer from amphibians to mammals took thirty-five years and required substantial innovation. Mammalian eggs are smaller, more fragile, and technically more difficult to manipulate than amphibian eggs. Many attempts failed, and some researchers questioned whether mammalian cloning from adult cells was possible at all.

In 1997, Ian Wilmut, Keith Campbell, and colleagues at the Roslin Institute in Edinburgh reported the birth of Dolly, a lamb generated by transferring the nucleus of an adult mammary gland epithelial cell into an enucleated sheep egg [5]. Dolly was the first mammal produced from an adult somatic cell and the demonstration that Gurdon's findings in frogs held across vertebrates.

A critical innovation was Campbell's insight that the cell cycle state of the donor nucleus matters. By inducing the donor cells to enter a quiescent state (G0) in a culture dish before nuclear transfer, achieved through withdrawing blood serum suppling nutrients vital for growth, the cell cycle of the donor nucleus could synchronised with the developmental programme of the recipient egg [5,6].

Dolly's birth catalysed work in somatic cell nuclear transfer (SCNT) across multiple species. Together with Wilmut our group at the Roslin Institute advanced cloning further in mice, sheep, cattle, and pigs, revealing both conserved features and species-specific barriers [7,8]. Each new species presented distinct challenges: different requirements for nuclear remodelling, different sensitivities to culture conditions, and different rates of developmental failure. These cross-species studies demonstrated that while the basic principle of nuclear reprogramming by the egg is conserved, the efficiency and reliability of the process depend heavily on the specific biology of the species involved.

SCNT also revealed that reprogramming by the egg is incomplete in most cases. Cloned animals frequently displayed abnormalities attributed to faulty epigenetic reprogramming, including large offspring syndrome in ruminants, placental defects, and respiratory difficulties [9]. These observations made clear that the egg contains factors that can reprogram a somatic nucleus, but not always with full fidelity.

Transcription factor reprogramming: the iPSC revolution

While SCNT demonstrated that reprogramming was possible using the natural machinery of the egg, it required access to eggs and was technically demanding. A fundamentally different approach emerged in 2006.

Kazutoshi Takahashi and Shinya Yamanaka at Kyoto University showed that mouse fibroblasts could be reprogrammed to a pluripotent state by introducing just four transcription factors: Oct3/4, Sox2, Klf4, and c-Myc, delivered using retroviruses [10]. The following year, the same group demonstrated the technique in human cells [11]. An independent group led by James Thomson achieved similar results using a partially different set of factors: Oct4, Sox2, Nanog, and Lin28 [12].

The cells produced by this method, induced pluripotent stem cells (iPSCs), resembled embryonic stem cells in their gene expression, their surface markers, their capacity for self-renewal, and their ability to form derivatives of all three germ layers. The discovery was greeted with considerable excitement because it offered a route to patient-specific pluripotent cells without the need for embryos or eggs.

The efficiency of the initial process was low, with fewer than 0.1% of treated cells successfully reprogramming, and the mechanism by which four transcription factors could reset an entire cellular identity remained poorly understood [10]. Subsequent work has improved efficiency, replaced viral delivery with non-integrating methods (mRNA, episomal vectors, small molecules), and elucidated some of the epigenetic barriers that reprogramming must overcome [13].

Yamanaka and Gurdon shared the 2012 Nobel Prize in Physiology or Medicine, explicitly linking the egg-mediated nuclear reprogramming of 1962 with the transcription factor-mediated reprogramming of 2006 as two routes to the same fundamental conclusion: that cellular identity is not permanent. Wilmut and Campbell were not included, a decision which downplayed the significance of pre-conditioning of somatic nuclei before transfer through serum deprivation. This not only served to co-ordinate the cell cycle status of the nuclear donor and enucleated egg cytoplasm but made the former receptive to reprogramming. In my opinion this was more than just a technical feat but possibly the first recognition of the importance of cell cycle progression in cellular differentiation that came to be appreciated over a decade later [14].

Direct reprogramming: bypassing pluripotency

If transcription factors can convert a fibroblast to a pluripotent cell, could different factors convert it directly to another specialised cell type, skipping the pluripotent state entirely?

This approach, called direct reprogramming or transdifferentiation, was demonstrated in 2010 when Masaki Ieda and colleagues converted mouse fibroblasts directly into beating cardiomyocyte-like cells using three cardiac transcription factors (Gata4, Mef2c, and Tbx5) [15]. Similar strategies have since been applied to generate neurons, hepatocytes, and other cell types from fibroblasts.

Direct reprogramming is attractive for applications in cell therapy because it avoids the tumour risk associated with the pluripotent intermediate and could in principle be faster and simpler for producing specific cell types. It is less attractive for applications that require large-scale expansion, since the converted cells typically have limited proliferative capacity. The approach remains at an earlier stage of development than iPSC technology and faces its own challenges in efficiency, maturity of the resulting cells, and reproducibility.

What reprogramming tells us

Taken together, these discoveries have reshaped our understanding of cellular identity. The genome of a differentiated cell is not a locked archive. It is a library with bookmarks, marks that can be removed and replaced under the right conditions. The egg cytoplasm does it through one set of mechanisms. Induction of cellular quiescence through serum deprivation in culture is another. Defined transcription factors do it through yet another. The fact that all these routes and likely more yet to be discovered work tells us something important: the regulatory layers that maintain cell identity, principally epigenetic modifications such as DNA methylation and histone modifications, are powerful but not irreversible [16].

This has practical consequences. iPSC technology now enables the generation of patient-specific cells for disease modelling, drug screening, and, increasingly, cell therapy. SCNT remains relevant for applications where nuclear reprogramming by the egg is preferred, including some reproductive biotechnology and conservation contexts. Direct reprogramming offers a potential shortcut for specific therapeutic applications.

For technology developers, the message is that reprogramming is not a single technique. It is a family of approaches, each with distinct requirements for delivery systems, culture conditions, quality control, and characterisation. The ancillary tools needed to support iPSC generation are not the same as those needed for SCNT or direct reprogramming, and the quality standards differ depending on whether the application is research, screening, or clinical use. Pillar 2 examines why ancillary technologies serving these workflows fail, including the specific challenges of reproducibility and scale-up.

‍ ‍

References

[1] Weismann A. Das Keimplasma: eine Theorie der Vererbung. Jena: Fischer; 1892.

[2] Briggs R, King TJ. Transplantation of living nuclei from blastula cells into enucleated frogs' eggs. Proc Natl Acad Sci USA. 1952;38(5):455-463. DOI: 10.1073/pnas.38.5.455

[3] Gurdon JB. The developmental capacity of nuclei taken from intestinal epithelium cells of feeding tadpoles. J Embryol Exp Morphol. 1962;10:622-640. DOI: 10.1242/dev.10.4.622

[4] Gurdon JB, Uehlinger V. "Fertile" intestine nuclei. Nature. 1966;210:1240-1241. DOI: 10.1038/2101240a0

[5] Wilmut I, Schnieke AE, McWhir J, Kind AJ, Campbell KH. Viable offspring derived from fetal and adult mammalian cells. Nature. 1997;385(6619):810-813. DOI: 10.1038/385810a0

[6] Campbell KH, McWhir J, Ritchie WA, Wilmut I. Sheep cloned by nuclear transfer from a cultured cell line. Nature. 1996;380(6569):64-66. DOI: 10.1038/380064a0

[7] De Sousa PA, Dobrinsky JR, Zhu J, Archibald AL, Ainslie A, Bosma W, Bowering J, Bracken J, Ferrier PM, Fletcher J, Gasparrini B, Harkness L, Johnston P, Ritchie M, Ritchie WA, Travers A, Albertini D, Dinnyes A, King TJ, Wilmut I. Somatic cell nuclear transfer in the pig: control of pronuclear formation and integration with improved methods for activation and maintenance of pregnancy. Biol Reprod. 2002;66(3):642-650. DOI: 10.1095/biolreprod66.3.642

[8] Wilmut I, Beaujean N, De Sousa PA, Dinnyes A, King TJ, Paterson LA, Wells DN, Young LE. Somatic cell nuclear transfer. Nature. 2002;419(6907):583-586. DOI: 10.1038/nature01079

[9] Rhind SM, Taylor JE, De Sousa PA, King TJ, McGarry M, Wilmut I. Human cloning: can it be made safe? Nat Rev Genet. 2003;4(10):855-864. DOI: 10.1038/nrg1205

[10] Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663-676. DOI: 10.1016/j.cell.2006.07.024

[11] Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861-872. DOI: 10.1016/j.cell.2007.11.019

[12] Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318(5858):1917-1920. DOI: 10.1126/science.1151526

[13] Stadtfeld M, Hochedlinger K. Induced pluripotency: history, mechanisms, and applications. Genes Dev. 2010;24(20):2239-2263. DOI: 10.1101/gad.1963910

[14] Pauklin S, Vallier L. The cell-cycle state of stem cells determines cell fate propensity. Cell. 2013;155(1):135-147. DOI: 10.1016/j.cell.2013.08.031

[15] Ieda M, Fu JD, Delgado-Olguin P, et al. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell. 2010;142(3):375-386. DOI: 10.1016/j.cell.2010.07.002

[16] Gurdon JB, Melton DA. Nuclear reprogramming in cells. Science. 2008;322(5909):1811-1815. DOI: 10.1126/science.1160810

‍ ‍

About StemCells.Help

StemCells.Help is an advisory consultancy that aids innovation and real-world impact of life science applications built on developmental and stem cell biology. Founded by Dr Paul De Sousa, it draws on over four decades of experience spanning early embryo development, animal cloning, pluripotent stem cell manufacturing, and technology commercialisation. If you build tools for these domains or work in an emerging application where the biology is the enabling technology, StemCells.Help can provide experienced scientific counsel to ground your decisions. To discuss your needs, talk to Paul.

ORCID: 0000-0003-0745-2504

Web: stemcells.help